Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern.

S P Newman, G Woodman, S W Clarke

Department of Thoracic Medicine, Royal Free Hospital and School of Medicine, London.

Antibiotic aerosol treatment is successful in treating Pseudomonas infection in some patients with cystic fibrosis, but the amount of drug reaching the lungs is unknown. The deposition patterns of carbenicillin aerosols delivered from two commercially available nebuliser systems (the Turret nebuliser plus Maxi compressor and the Inspiron nebuliser plus Traveller compressor) have been compared in six patients with cystic fibrosis during tidal breathing. The aerosol mass median diameters were 3.2 and 7.3 microns. In addition, the aerosol from the Turret-Maxi nebuliser system was inhaled by a combination of tidal and deep breathing. After two minutes' breathing via a mouthpiece the mean (SEM) deposition in the lungs was 15.60 (1.5) mg carbenicillin with the Turret nebuliser plus Maxi compressor, but only 6.54 (1.09) mg with the Inspiron nebuliser plus Traveller compressor; the distribution pattern within the lung was significantly more peripheral with the former nebuliser system. These differences may be ascribed partly to the smaller droplet size from the Turret system and partly to the higher nebulisation rate from the more powerful Maxi compressor. Tidal plus deep breathing produced a further small but non-significant increase in lung aerosol deposition. A seventh patient, who failed to complete the trial, had little aerosol deposited in his lungs because he inhaled through his nose. These results emphasise the importance of correct selection of nebuliser equipment for antibiotic aerosol treatment.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• FAUROUX, B., ITTI, E., PIGEOT, J., ISABEY, D., MEIGNAN, M., FERRY, G., LOFASO, F., WILLEMOT, J.-M., CLÉMENT, A., HARF, A. (2000). Optimization of Aerosol Deposition by Pressure Support in Children with Cystic Fibrosis . An Experimental and Clinical Study. Am. J. Respir. Crit. Care Med. 162: 2265-2271 [Abstract] [Full Text]  
• Laube, B. L., Jashnani, R., Dalby, R. N., Zeitlin, P. L. (2000). Targeting Aerosol Deposition in Patients With Cystic Fibrosis : Effects of Alterations in Particle Size and Inspiratory Flow Rate. Chest 118: 1069-1076 [Abstract] [Full Text]  
• Wilson, D., Burniston, M., Moya, E., Parkin, A., Smye, S., Robinson, P., Littlewood, J. (1999). Improvement of nebulised antibiotic delivery in cystic fibrosis. Arch. Dis. Child. 80: 348-352 [Abstract] [Full Text]  
• Ramsey, B. W., Dorkin, H. L., Eisenberg, J. D., Gibson, R. L., Harwood, I. R., Kravitz, R. M., Schidlow, D. V., Wilmott, R. W., Astley, S. J., McBurnie, M. A., Wentz, K., Smith, A. L. (1993). Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis. NEJM 328: 1740-1746 [Abstract] [Full Text]  
• Baskin, M. I., Abd, A. G., Ilowite, J. S. (1990). Regional Deposition of Aerosolized Pentamidine: Effects of Body Position and Breathing Pattern. ANN INTERN MED 113: 677-683 [Abstract]